TAM
ALNY icon

Tocqueville Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Tocqueville Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,000
Closed -$437K – 704
2020
Q3 		$437K Hold
3,000
– – 0.01% 512
2020
Q2 		$444K Hold
3,000
– – 0.01% 505
2020
Q1 		$327K Hold
3,000
– – 0.01% 526
2019
Q4 		$346K Buy
+3,000
New +$299K 0.01% 618
2019
Q2 		– Sell
-7,700
Closed -$720K – 774
2019
Q1 		$720K Buy
+7,700
New +$644K 0.01% 525
2018
Q4 		– Sell
-42,481
Closed -$3.72M – 747
2018
Q3 		$3.72M Sell
42,481
-12,235
-22% -$1.23M 0.05% 337
2018
Q2 		$5.39M Sell
54,716
-21,745
-28% -$2.16M 0.07% 284
2018
Q1 		$9.11M Sell
76,461
-77,575
-50% -$10M 0.12% 193
2017
Q4 		$19.6M Buy
154,036
+133,261
+641% +$16.7M 0.22% 122
2017
Q3 		$2.44M Buy
20,775
+4,200
+25% +$358K 0.03% 421
2017
Q2 		$1.32M Buy
16,575
+2,400
+17% +$153K 0.02% 467
2017
Q1 		$726K Sell
14,175
-2,830
-17% -$131K 0.01% 531
2016
Q4 		$637K Sell
17,005
-93,440
-85% -$3.91M 0.01% 558
2016
Q3 		$7.49M Sell
110,445
-3,525
-3% -$249K 0.09% 233
2016
Q2 		$6.32M Sell
113,970
-525
-0.5% -$33.1K 0.08% 257
2016
Q1 		$7.19M Buy
114,495
+4,725
+4% +$314K 0.1% 226
2015
Q4 		$10.3M Sell
109,770
-575
-0.5% -$53.3K 0.14% 174
2015
Q3 		$8.87M Buy
110,345
+24,810
+29% +$2.76M 0.12% 210
2015
Q2 		$10.3M Buy
85,535
+1,950
+2% +$233K 0.12% 205
2015
Q1 		$8.73M Buy
83,585
+55,335
+196% +$5.61M 0.1% 226
2014
Q4 		$2.74M Sell
28,250
-2,000
-7% -$185K 0.03% 426
2014
Q3 		$2.36M Sell
30,250
-550
-2% -$35.5K 0.03% 406
2014
Q2 		$1.95M Buy
30,800
+8,300
+37% +$493K 0.02% 475
2014
Q1 		$1.51M Sell
22,500
-5,000
-18% -$387K 0.02% 401
2013
Q4 		$1.77M Hold
27,500
– – 0.02% 394
2013
Q3 		$1.76M Sell
27,500
-1,200
-4% -$59.8K 0.02% 448
2013
Q2 		$890K Buy
+28,700
New +$764K 0.01% 523

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Tocqueville Asset Management's ALNY Position: Q4 2020 in Review

Tocqueville Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2020, closing a stake of 3,000 shares — an estimated $437K sold.

Tocqueville Asset Management first reported a position in ALNY in Q2 2013 and held it in 27 quarters. The position peaked at $19.6M in Q4 2017. 376 funds tracked by Wall St. Rank hold ALNY as of Q4 2020.

  • Tocqueville Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Tocqueville Asset Management sold 3,000 Alnylam Pharmaceuticals shares in Q4 2020, an estimated $437K.
  • Tocqueville Asset Management first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 27 quarters.
  • Tocqueville Asset Management's Alnylam Pharmaceuticals position peaked at $19.6M in Q4 2017.
  • 376 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2020.

Based on Tocqueville Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.